DEFA14A: TransCode Amends Filing, Details ABCJ Acquisition & $25M Investment

TransCode Therapeutics, Inc. filed an amendment to correct the price per share for its Series B Preferred Stock, detailing the acquisition of ABCJ, LLC and a concurrent $25 million private placement investment from DEFJ, LLC.

Summary

• The filing is an Amendment No. 1 to the Current Report on Form 8-K, solely to correct an inadvertently included incorrect price per share of Series B Preferred Stock.
• TransCode Therapeutics, Inc. (the Company) acquired 100% of the issued and outstanding membership interests of ABCJ, LLC from DEFJ, LLC.
• In exchange for ABCJ, the Company issued DEFJ 83,285 shares of common stock (representing 9.99% of common stock outstanding prior to closing) and 1,152.9568 shares of Series A Non-Voting Convertible Preferred Stock.
• The Company also agreed to make up to $95,000,000 in contingent milestone payments to DEFJ upon the achievement of certain milestones related to the ABCJ acquisition.
• Concurrently, DEFJ, LLC agreed to purchase 223.7337 shares of Series B Non-Voting Preferred Stock from the Company in a private placement for an aggregate purchase price of approximately $25 million.
• The $25 million investment consisted of a cash subscription amount of approximately $20 million and a promissory note in the aggregate principal amount of approximately $5 million.
• Each share of Series B Preferred Stock was purchased at a price of $111,740 per share.
• The promissory note has a principal amount of approximately $5 million, accrues interest at 4% per annum, and is due on January 1, 2026, secured by 44.7467 shares of Series B Preferred Stock.
• Each share of Series A Preferred Stock and Series B Preferred Stock is convertible into 10,000 shares of Common Stock.
• Tungsten Advisors received 59.2255 shares of Series A Preferred Stock as partial compensation for financial advisory and placement agent services.
• The Board of Directors unanimously approved the acquisition, investment, and related transactions.
• The Company agreed to hold a stockholders meeting to approve the conversion of Series A Preferred Stock into common stock and a change of control under Nasdaq Listing Rules.
• A Contingent Value Rights (CVR) Agreement was entered into, entitling holders of common stock as of October 20, 2025, to 50% of Net Proceeds from any Upfront Payment or Milestone Payment received by the Company in a given calendar quarter, for a term of seven years.
• The Company is required to file a resale registration statement with the SEC within 75 calendar days for the shares issued to DEFJ.
• DEFJ has a right, but not an obligation, to repurchase ABCJ's membership interests from the Company upon the occurrence of certain events.

Sentiment

Score: 7

Explanation: The filing details a significant acquisition and a substantial capital raise, which are generally positive for growth and financial stability. The potential for contingent milestone payments and CVRs adds further upside. However, the potential for significant dilution from preferred stock conversion and the need for stockholder approvals introduce some uncertainty, preventing a higher score. The correction of a previous error is a neutral event.

Positives

• The acquisition of 100% of ABCJ, LLC expands the company's asset base and strategic capabilities.
• A significant capital infusion of approximately $25 million, including approximately $20 million in cash, strengthens the company's financial position and provides funding for operations and drug development.
• The potential for up to $95 million in contingent milestone payments from the acquisition provides a substantial future revenue opportunity.
• The establishment of a Contingent Value Rights (CVR) Agreement offers existing common stockholders a mechanism to receive future cash distributions from the monetization of legacy non-cash assets.
• The Board of Directors unanimously approved all material definitive agreements and related transactions, indicating strong internal alignment.

Negatives

• The issuance of Series A and Series B Preferred Stock, convertible into common stock, poses a significant risk of dilution for existing common stockholders upon conversion.
• The requirement for stockholder approval for the conversion of Series A Preferred Stock and a change of control introduces a potential hurdle and uncertainty.
• DEFJ, LLC retains a right to repurchase ABCJ's membership interests under certain conditions, which could reverse the acquisition and impact long-term strategic plans.

Risks

• Significant dilution risk for existing common stockholders from the potential conversion of Series A and Series B Preferred Stock into common shares.
• Uncertainty regarding obtaining stockholder approval for the conversion of Series A Preferred Stock and the change of control under Nasdaq Listing Rules.
• Contingent milestone payments and CVR distributions are dependent on the achievement of specific milestones and the generation of net proceeds, which are not guaranteed.
• DEFJ's contractual right to repurchase ABCJ's membership interests introduces a potential for the acquired entity to revert to the seller under certain future events.
• The promissory note from DEFJ to TransCode is secured by Series B Preferred Stock, which could imply a risk for DEFJ if TransCode defaults, but for TransCode, it's a receivable with a specific due date.

Future Outlook

The company expects to integrate ABCJ, LLC and leverage the approximately $25 million investment to advance drug development (40% of funds) and support general corporate operations (60% of funds). Future actions include holding a stockholder meeting for conversion and change of control approvals, and filing a resale registration statement for DEFJ's shares. The CVR agreement suggests a future focus on monetizing legacy non-cash assets.

Management Comments

• The Board of Directors of the Company (the Board) unanimously approved the Purchase Agreement, the Investment Agreement and the related transactions.

Industry Context

The acquisition of ABCJ, LLC and the associated capital raise suggest a strategic move to expand TransCode Therapeutics' asset base or capabilities, likely within the biotechnology or pharmaceutical sector. This aligns with broader industry trends of consolidation or strategic partnerships aimed at accelerating drug development or expanding market reach. The capital raise indicates a need for funding, which is common in the R&D-intensive biotech industry, where significant capital is often required to advance therapeutic pipelines.

Comparison to Industry Standards

• The capital raise of approximately $25 million, with a significant portion as cash, represents a moderate to substantial funding round for a small-cap biotechnology company, comparable to funding secured by emerging biopharma firms for advancing early-to-mid-stage clinical trials, such as a Series B round for a company developing a novel oncology therapeutic or a platform technology company expanding its R&D capabilities.
• The use of convertible preferred stock as a financing mechanism is a standard practice in the biotech industry, often employed by companies seeking strategic investors or institutional capital, similar to how many pre-revenue or clinical-stage biotechs structure their private placements to provide downside protection and upside participation.
• Contingent milestone payments, up to $95 million in this acquisition, are a common feature in biotech M&A, particularly when the acquired assets are in early development. This structure aligns with industry benchmarks for risk-sharing and incentivizing post-acquisition performance, mirroring deals for unproven drug candidates or intellectual property portfolios.
• The Contingent Value Rights (CVR) agreement, designed to distribute 50% of net proceeds from legacy non-cash assets, represents a strategic approach to monetize non-core assets, a practice sometimes seen in larger pharmaceutical divestitures or spin-offs to unlock shareholder value from non-strategic pipelines or assets.

Corporate Governance

Related Party Transactions

• DEFJ, LLC is a significant related party, acting as both the seller of ABCJ, LLC to TransCode Therapeutics and the investor in the private placement, purchasing Series B Preferred Stock.
• Tungsten Advisors (through Finalis Securities LLC) received 59.2255 shares of Series A Preferred Stock as partial compensation for its financial advisory services in connection with the acquisition and as placement agent for the investment.

Stakeholder Impact

• Shareholders: Face potential significant dilution from the conversion of Series A and Series B Preferred Stock. Will have the opportunity to receive future cash distributions through CVRs. Required to vote on key corporate governance matters (conversion and change of control).
• Company (TransCode Therapeutics): Benefits from a strengthened financial position due to the $25 million capital raise and expanded asset base through the ABCJ acquisition. Gains operational flexibility with funds allocated to drug development and general corporate purposes.
• DEFJ, LLC: Becomes a significant shareholder (common and preferred) and creditor (promissory note holder) of TransCode Therapeutics. Stands to receive contingent milestone payments and holds a repurchase right for ABCJ, providing strategic flexibility.
• Tungsten Advisors: Received compensation in Series A Preferred Stock for its advisory and placement services, aligning its interests with the company's future performance.

Next Steps

• Hold a stockholders meeting to approve the conversion of Series A Preferred Stock into Common Stock.
• Hold a stockholders meeting to approve a change of control under Nasdaq Listing Rules 5110 and 5635(b).
• File a proxy statement on Schedule 14A with the SEC within 30 days following receipt of all required financial statements.
• File a resale registration statement with the SEC within 75 calendar days following the closing of the Acquisition and Investment.
• Use 40% of the Subscription Amount for drug development purposes.
• Use 60% of the Subscription Amount for general corporate purposes, including operating expenses, insurance, and administration.

Key Dates

Recommendation

The company has secured a significant capital infusion of approximately $25 million and acquired ABCJ, LLC, which are generally positive developments for growth and financial stability. The potential for up to $95 million in contingent milestone payments further adds to the upside. However, the issuance of a substantial amount of Series A and Series B Preferred Stock, convertible into common stock, presents a considerable risk of dilution for existing common shareholders. The requirement for stockholder approval for these conversions and a change of control introduces an element of uncertainty. While the Contingent Value Rights offer a mechanism for existing shareholders to benefit from legacy assets, the overall picture suggests a 'hold' recommendation. Investors should monitor the outcome of the stockholder votes and the company's execution on its strategic initiatives and drug development pipeline before making further investment decisions.

Keywords

TransCode Therapeutics, RNAZ, SEC filing, DEFA14A, acquisition, private placement, preferred stock, common stock, contingent value rights, CVR, DEFJ, ABCJ, capital raise, dilution, Nasdaq, biotechnology, drug development